**
In a startling revelation, internal government records have uncovered a meeting between top officials from the Trump administration’s Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson, to discuss ongoing litigation related to the company’s glyphosate weed killer. This meeting, held on June 17, 2025, appears to have set the stage for a series of actions by the administration aimed at bolstering Bayer’s legal position against claims that its herbicides, particularly Roundup, are linked to cancer.
Unpacking the Meeting
The significant gathering included high-ranking EPA officials such as Lee Zeldin, the agency’s administrator, and Nancy Beck, the Principal Deputy Assistant Administrator. They convened with Bayer executives to address “litigation issues,” including potential Supreme Court actions regarding glyphosate, which has been at the centre of thousands of lawsuits claiming it causes cancer.
Bayer has been grappling with the financial repercussions of these lawsuits, which have cost the company billions in settlements. The strategy discussed during the meeting revolved around persuading the Supreme Court that if the EPA does not mandate a cancer warning on glyphosate products, Bayer should not be held liable for not issuing such warnings themselves.
Political Support for Bayer
The Trump administration’s backing for Bayer’s position has intensified following the June meeting. Notably, on December 1, 2025, Solicitor General D. John Sauer, appointed by the administration, urged the Supreme Court to accept Bayer’s case. The Court obliged, scheduling a hearing for April 27, 2026. Furthermore, the administration invoked the Defense Production Act in February 2026 to safeguard glyphosate production, effectively granting “immunity” to Bayer and other manufacturers.
This series of supportive actions raises critical questions about the influence of corporate interests on public health policy. Nathan Donley, Environmental Health Science Director at the Center for Biological Diversity, expressed concern over the apparent prioritisation of corporate profits over the health of the American public. “When the CEO of one of the largest companies in the world meets with political appointees in a US regulatory office, it illustrates the extent of corporate power in decisions that directly affect public health,” he stated.
Industry Influence Under Scrutiny
Concerns about the meeting and the subsequent support from the Trump administration have drawn criticism from various quarters. Legal experts and advocates are alarmed by the implications of such private discussions. Whitney Di Bona, a consumer safety advocate, noted, “It’s troubling that a major pesticide company’s CEO can privately meet with the EPA to discuss limiting liability while the voices of those alleging harm are silenced.”
The disparities in access to regulatory officials between industry leaders and affected citizens reflect a troubling trend. Naomi Oreskes, a Harvard professor investigating corporate influence on regulation, highlighted the pattern of industry leaders enjoying privileges that the general public does not.
Zen Honeycutt, founder of Moms Across America, echoed these sentiments, indicating that such meetings between corporate executives and government officials are part of a long-standing trend of regulatory capture by chemical companies. Her organisation has actively engaged with the EPA, yet has seen little action in terms of addressing the risks posed by harmful pesticides.
Why it Matters
The revelations surrounding Bayer’s interactions with the Trump administration’s EPA are deeply concerning for public health advocates and citizens alike. They underscore a growing trend where corporate interests may overshadow the rights and health of individuals, particularly those adversely affected by toxic products. As the legal battles over glyphosate continue, the implications of these meetings could set a precedent for corporate influence over regulatory decisions, ultimately shaping the landscape of public health policy in the United States. The stakes are high, and the need for transparency and accountability in regulatory affairs has never been more urgent.
